Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- World cancer report 2008.World Health Organization, Lyon (France)2008
- Cancer statistics, 2013.CA Cancer J Clin. 2013; 63: 11-30
- Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.Am J Pathol. 2004; 164: 1511-1518
- Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.Science. 2010; 330: 228-231
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.J Pathol. 2010; 221: 49-56
- Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.Am J Surg Pathol. 2013; 37: 356-367
- Epidemiology of low-grade serous ovarian cancer.Am J Obstet Gynecol. 2008; 198 ([discussion: 459.e8–9]): 459.e1-459.e8
- Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.Histopathology. 2013; 62: 44-58
- New insights into ovarian cancer pathology.Ann Oncol. 2012; 23: x111-x117
- Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway.J Pathol. 2008; 216: 103-110
- Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.Am J Surg Pathol. 2009; 33: 844-853
- Mutation of the PIK3CA gene in ovarian and breast cancer.Cancer Res. 2004; 64: 7678-7681
- Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.Cancer Res. 2000; 60: 7052-7056
- Endometriosis.N Engl J Med. 2009; 360: 268-279
- Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.Cancer Res. 1998; 58: 2095-2097
- Ovarian cancer.Annu Rev Pathol. 2009; 4: 287-313
- Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.Cancer Cell. 2007; 11: 321-333
- Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome.Am J Pathol. 1999; 155: 527-536
- Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation.J Pathol. 2001; 194: 59-67
- Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm.Hum Pathol. 2011; 42: 918-931
- Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.Gynecol Oncol. 2003; 90: 378-381
- Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas.Am J Surg Pathol. 1999; 23: 617-635
- Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors.Arch Pathol Lab Med. 2008; 132: 1753-1760
- The fallopian tube-peritoneal junction: a potential site of carcinogenesis.Int J Gynecol Pathol. 2011; 30: 4-11
- Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.Am J Surg Pathol. 2007; 31: 854-869
- Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.Pathology. 2011; 43: 420-432
- The role of the Fallopian tube in the origin of ovarian cancer.Am J Obstet Gynecol. 2013; https://doi.org/10.1016/j.ajog.2013.04.019
- Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.J Clin Oncol. 2007; 25: 3985-3990
- Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.Mod Pathol. 2009; 22: 1133-1138
- Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.Gynecol Oncol. 2006; 100: 58-64
- The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.Am J Surg Pathol. 2006; 30: 230-236
- Are all pelvic (nonuterine) serous carcinomas of tubal origin?.Am J Surg Pathol. 2010; 34: 1407-1416
- Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.Clin Cancer Res. 2005; 11: 6116-6126
- A candidate precursor to serous carcinoma that originates in the distal fallopian tube.J Pathol. 2007; 211: 26-35
- Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase.Mod Pathol. 2010; 23: 844-855
- The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.Am J Surg Pathol. 2010; 34: 433-443
- Ovarian cancer and hormone replacement therapy in the Million Women Study.Lancet. 2007; 369: 1703-1710
- Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk.Obstet Gynecol. 2007; 109: 597-607
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.Lancet. 2010; 376: 245-251
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.Lancet. 2010; 376: 235-244
- Molecular pathology of endometrial carcinoma; practical aspects from the diagnostic and therapeutical view points.J Clin Pathol. 2009; 62: 777-785
- Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma.Am J Pathol. 1996; 148: 1671-1678
- Microsatellite instability in sporadic endometrial carcinoma.J Natl Cancer Inst. 1994; 86: 1216-1221
- Molecular pathology of endometrial carcinoma.Histopathology. 2013; 62: 111-123
- Microsatellite instability in endometrial carcinomas: frequent replication errors in tumors of early onset and/or of poorly differentiated type.Genes Chromosomes Cancer. 1995; 14: 128-132
- Genetic instability of microsatellites in endometrial carcinoma.Cancer Res. 1993; 53: 5100-5103
- Molecular pathology of endometrial hyperplasia and carcinoma.Hum Pathol. 2001; 32: 569-577
- High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.Cancer Res. 2005; 65: 10669-10673
- Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinomas with microsatellite instability.Cancer. 2000; 88: 2290-2297
- PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.Mod Pathol. 2008; 21: 131-139
- Expression profiling of 22 genes involved in the PI3K–AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.Mod Pathol. 2010; 23: 694-702
- A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.Clin Cancer Res. 2011; 17: 1331-1340
- Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.Gynecol Oncol. 2003; 91: 463-469
- Clear-cell and papillary serous cancer: treatment options.Best Pract Res Clin Obstet Gynaecol. 2001; 15: 433-446
- Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women.Gynecol Oncol. 1997; 65: 206-212
- Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences.Am J Surg Pathol. 2007; 31: 979-987
- Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.Cancer Res. 2003; 63: 6195-6199
- Uterine papillary serous carcinoma: state of the state.Curr Oncol Rep. 2008; 10: 505-511
- Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease.Gynecol Oncol. 2001; 81: 279-286
- Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study.Int J Gynecol Pathol. 2013; 32: 181-187
- Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?.Cancer. 2004; 101: 2214-2221
- Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma.Am J Surg Pathol. 1982; 6: 93-108
- The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer.Gynecol Oncol. 2006; 101: 470-475
- Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation.Hum Pathol. 1995; 26: 1260-1267
- p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.Am J Pathol. 1997; 150: 177-185
- Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells.Oncogene. 1990; 5: 137-145
- HER1/EGFR targeting: refining the strategy.Oncologist. 2004; 9: 58-67
- Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.Cancer. 2005; 104: 1391-1397
- Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.J Clin Oncol. 2004; 22: 3126-3132
- Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.Cancer. 1994; 73: 2380-2385
- Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.Br J Cancer. 2008; 98: 1076-1084
- Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.Gynecol Oncol. 2009; 113: 370-373
- E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium.Obstet Gynecol. 2002; 100: 1290-1295
- Use of mutation profiles to refine the classification of endometrial carcinomas.J Pathol. 2012; 228: 20-30
- Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.Virchows Arch. 2004; 444: 213-223
- Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.Gynecol Oncol. 1994; 53: 84-92
- Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus.Cancer. 2000; 88: 2782-2786
- The rationale for comprehensive surgical staging in endometrial carcinosarcoma.Gynecol Oncol. 2005; 99 ([author reply: 522–3]): 521-522
- Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas.Int J Gynecol Cancer. 2002; 12: 687-690
- Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component.Mod Pathol. 2011; 24: 1368-1379
Article info
Identification
Copyright
© 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
